April 7, 2014
by Endia Vereen
JURIST Guest Columnist Kristen Swift, Widener University School of Law Class of 2014, discusses Merck & Co.'s NuvaRing settlement and the company's corporate governance policies...Recently, Merck & Co. made a major splash across headlines by offering NuvaRing plaintiff's a $100 million ...[read more]
March 22, 2014
by Endia Vereen
JURIST Guest Columnist Melissa Brumer Fordham University School of Law Class of 2015, discusses the differences in settlement amounts between recent contraceptive lawsuits and argues that Merck may be getting out much more cheaply than its competitors...On Friday, February 7, 2014, Merck & Co... ...[read more]
March 5, 2014
by Endia Vereen
JURIST Guest Columnist Tara Pakrouh, Widener University School of Law Class of 2015, discusses Merck & Co.'s $100 million settlement concerning the corporation's NuvaRing contraceptive device, the board's liability and the fiduciary duties it owes to its shareholders...In a December 2000 email ...[read more]
February 8, 2014
by Matthew Pomy
Merck & Co. agreed to pay $100 million to settle thousands of lawsuits concerning Merck's NuvaRing contraceptive device. The lawsuits allege that NuvaRing potentially causes fatal blood clots. The settlement will provide an average payment of over $58,000 per case. This settlement is less than ...[read more]

Support JURIST

We rely on our readers to keep JURIST running

 Donate now!

© Copyright JURIST Legal News and Research Services, Inc., 2013.